SAVA Technologies

Sava Technologies is a London-based health technology company developing a minimally invasive, multi-molecule wearable biosensor platform for real-time health monitoring. Founded by bioengineers from Imperial College London, the company's proprietary microsensing technology detects biomarkers in the interstitial fluid just beneath the skin, providing accurate data without the need for deep-penetrating filaments or blood draws. Its lead product is a pain-free continuous glucose monitor (CGM) that has demonstrated 10-day accuracy in clinical trials, positioning it as a more affordable and accessible alternative to existing CGMs. Beyond diabetes, Sava's modular platform is designed to monitor a range of biomarkers including lactate, cortisol, and ketones, aiming to transition healthcare from reactive treatment to proactive, personalized monitoring. The company recently secured significant Series A funding to accelerate regulatory approval and scale its automated manufacturing capabilities.